Являетесь ли Вы специалистом здравоохранения?

Информация размещенная далее является только для специалистов здравоохранения

Нет

КОНКОР

Библиотека ссылок по препарату Бисопролол

Gillman MW, Kannel WB, Belanger A, D'Agostino RB, influence of heart rate on morality among persons with hypertension: the Framingham Study. Am Heart J. 1993 Apr;125(4):1148-54



1) Previous studies have shown positive associations between heart rate and both all-cause and cardiovascular morality.

Подробнее...

Mancia G, Fagard R, Narkiewicz K et al 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357.

2) The 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines continue to adhere to ...

Подробнее...

Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J. 2011 Oct;32(20):2499-506. doi: 10.1093/eurheartj/ehr177. Epub 2011 Jun 22. Review.


3) Raised levels of blood pressure result from the complex interplay of environmental and genetic factors...

Подробнее...

Palatini P. Heart rate and the cardiometabolic risk. Curr Hypertens Rep. 2013 Jun;15(3):253-9. doi: 10.1007/s11906-013-0342-7. Review.



4) Resting heart rate is a well recognized marker of autonomic nervous system tone, and in many population studies ...

Подробнее...

Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009 Oct;54(4):690-7. doi: 10.1161/HYPERTENSIONAHA.108.119883. Epub 2009 Aug 31.

5) Methodological refinements in the assessment of human sympathetic cardiovascular drive have allowed throughout...

Подробнее...

Grassi G, Seravalle G, Quarti-Trevano F. The 'neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol. 2010 May;95(5):581-6. doi: 10.1113/expphysiol.2009.047381. Epub 2009 Dec 11.

6) Data collected in experimental animals and in humans support the hypothesis that sympathetic neural mechanisms ...

Подробнее...

Egan BM, Basile J, Chilton RJ, Cohen JD. Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich). 2005 Jul;7(7):409-16.


7) Randomized controlled clinical trials document that beta blockers reduce cardiovascular morbidity and mortality, ...

Подробнее...

Cruickshank JM. Beta-blockers and diabetes: the bad guys come good. Cardiovasc Drugs Ther. 2002 Sep;16(5):457-70.



8) Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity. It is associated with ...

Подробнее...

Poitras, V. J., Pyke, K. E. The impact of acute mental stress on vascular endothelial function: evidence, mechanisms and importance. Int J Psychophysiol. 2013 May;88(2):124-35. doi: 10.1016/j.ijpsycho.2013.03.019. Epub 2013 Apr 3.

9) Cardiovascular disease is a principle cause of morbidity and mortality worldwide, and it has a complex etiology ...

Подробнее...

Klein LW, Pichard AD, Holt J, Smith H, Gorlin R, Teichholz LE. Effects of chronic tobacco smoking on the coronary circulation. J Am Coll Cardiol. 1983 Feb;1(2 Pt 1):421-6.

10) The effects of chronic smoking on the coronary circulation were studied by evaluating the coronary vascula ...

Подробнее...

Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med. 1976 Sep 9;295(11):573-7.

11) We studied the effects of cigarette smoking, sham smoking and smoking during adrenergic blockade in 10 subjects ...

Подробнее...

Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS, Levy D. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation. 2005 Mar 8;111(9):1121-7. Epub 2005 Feb 21.

12) BACKGROUND:Factors leading differentially to the development of isolated diastolic (IDH), systolic-diastolic (SDH) ...

Подробнее...

Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. Epub 2007 Apr 12.






13) In myocardial ischaemia and heart failure, beta-blockers with intrinsic sympathomimetic activity (ISA) e.g. ...

Подробнее...

Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012 Mar 1;109(5):685-92. doi: 10.1016/j.amjcard.2011.10.025. Epub 2011 Dec 9.

14) A high heart rate (HR) predicts future cardiovascular events. We explored the predictive value of HR in patients ...

Подробнее...

Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993 Apr;125(4):1148-54.





15) Previous studies have shown positive associations between heart rate and both all-cause and cardiovascular mortality ...

Подробнее...

Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension. 1999 Jan;33(1):44-52.

16) The aim of the present study was to assess the effects of high heart rate on mortality in different subgroups in a French ...

Подробнее...

Jouven X, Zureik M, Desnos M, Guérot C, Ducimetière P. Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res. 2001 May;50(2):373-8.

17) OBJECTIVE: A relative hyperadrenergic tone related to abnormalities of the autonomic nervous system is suspected ...

Подробнее...

Linnemann B, Janka HU. Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. Exp Clin Endocrinol Diabetes. 2003 Jun;111(4):215-22.

18) AIM: The Bremen Diabetes Study is an observation study to characterise type 2 diabetic patients at high risk ...

Подробнее...

Kasprzak JD, Stępińska J, Wożakowska Kapłon B, Drożdż J, Grajek S, Opolski G, Rynkiewicz A, Tykarski A, Filipiak KJ; Polish Cardiac Society Working Group on Cardiovascular Drug Therapy. [Optimum heart rate - the current goal of cardiovascular therapy. Position statement of the Polish Cardiac Society Working Group on Cardiovascular Drug Therapy]. Kardiol Pol. 2012;70(10):1081-94. Polish.

19) ...

Подробнее...

Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M; Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007 Aug 28;50(9):823-30. Epub 2007 Aug 13.

20) The importance of resting heart rate (HR) as a prognostic factor and potential therapeutic target is not yet generally accepted. ...

Подробнее...

Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005 May;26(10):967-74. Epub 2005 Mar 17.


21) AIMS: Heart rate reduction is the cornerstone of the treatment of angina. The purpose of this study was to explore ...

Подробнее...

Ho JE, Bittner V, Demicco DA, Breazna A, Deedwania PC, Waters DD. Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial). Am J Cardiol. 2010 Apr 1;105(7):905-11. doi: 10.1016/j.amjcard.2009.11.035.

22) The heart rate at rest (HR) is a predictor of cardiovascular (CV) mortality. However, its effect on nonfatal CV ...

Подробнее...

Tardif JC. Heart rate as a treatable cardiovascular risk factor. Br Med Bull. 2009;90:71-84. doi: 10.1093/bmb/ldp016. Epub 2009 May 27.





23) BACKGROUND: Although several epidemiological studies demonstrate the association between resting heart rate (HR) ...

Подробнее...

Axsom K, Bangalore S. Heart rate in coronary artery disease: should we lower it? Curr Treat Options Cardiovasc Med. 2013 Feb;15(1):118-28. doi: 10.1007/s11936-012-0217-2.





24) Elevated resting heart rate is an independent risk factor for cardiovascular morbidity and mortality in patients ...

Подробнее...

Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J. 2007 Dec;28(24):3012-9. Epub 2007 Nov 2

25) AIMS: The impact on mortality outcomes of beta-blockers and calcium blockers in post-myocardial infarction (MI) ...

Подробнее...

Custodis F, Reil JC, Laufs U, Böhm M. Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. J Cardiol. 2013 Sep;62(3):183-7. doi: 10.1016/j.jjcc.2013.02.018. Epub 2013 Jun 24.

26) Heart rate is a predictor of cardiovascular and all-cause mortality in the general population and in patients with ...

Подробнее...

Procoralan (ivabradine) Summary of Product Characteristics, revision dated 7 June 2016.






27) ...

Подробнее...

Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Sep 6;372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8. Epub 2008 Aug 29.

28) BACKGROUND: Ivabradine specifically inhibits the I(f) current in the sinoatrial node to lower heart rate,...

Подробнее...

Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Erratum in: Lancet. 2010 Dec 11;376(9757):1988.

29) BACKGROUND: Chronic heart failure is associated with high mortality and morbidity. Raised resting heart rate ...

Подробнее...

Ferrari R, Fox KM. The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY. Eur Heart J. 2015 Aug 14;36(31):2042-2046. Epub 2015 Apr 28.




30) The results of the SIGNIFY (study assessing the morbidity–mortality benefits of the If inhibitor ivabradine ...

Подробнее...

Ferrari R, Fox KM. The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY. Eur Heart J. 2015 Aug 14;36(31):2042-2046. Epub 2015 Apr 28.

31) BACKGROUND: An elevated heart rate is an established marker of cardiovascular risk. Previous analyses ...

Подробнее...